Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864536 | 0.76 | CRHBP (0.37) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL27913228 | 0.72 | CRHBP (0.40) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL11710268 | 0.72 | CRHBP (0.37) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL13503079 | 0.72 | CRHBP (0.37) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL4899652 | 0.69 | BCL2 (0.37) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL28159300 | 0.68 | ERN1 (0.41) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| Methane SCHEMBL27899889 | 0.67 | CRHBP (0.36) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL6251001 | 0.67 | ALDH1A1 (0.43) | CRHBPCRHR2KEAP1NFE2L2KDM4E | |
| SCHEMBL51330 | 0.65 | CRHBP (0.61) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL29359446 | 0.65 | CRHBP (0.61) | CRHBPCRHR2KEAP1NFE2L2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509220-A4 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4- 2-METHYL-3(3-METHYL-2-BUTENYL)-2-OXIRANYL -1-OXASPIRO 2,5 OCTAN-6-ONE | MYCOPLUS CO LTD (KR) | 2009-04-01 | — | — | EP | disclosed |
| US-20050124690-A1 | Pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4-[2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl]-1-oxaspiro[2,5]octan-6-one | MYCOPLUS CO., LTD. (KR) | 2005-06-09 | — | — | US | disclosed |
| EP-1509220-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4- 2-METHYL-3(3-METHYL-2-BUTENYL)-2-OXIRANYL]-1-OXASPIRO 2,5]OCTAN-6-ONE | Mycoplus Co., Ltd. (KR) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003094908-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4-[2-METHYL-3(3-METHYL-2-BUTENYL)-2-OXIRANYL]-1-OXASPIRO[2,5]OCTAN-6-ONE | MYCOPLUS CO., LTD. (KR) | 2003-11-20 | — | — | WO | disclosed |
| US-3971725-A | 2-Mercaptoquinoxaline-1-oxides, salts thereof and 2-(1-oxoquinoxalinyl)disulfides in detergent compositions | COLGATE-PALMOLIVE COMPANY (US) | 1976-07-27 | — | — | US | disclosed |
| US-3971725-A | 2-Mercaptoquinoxaline-1-oxides, salts thereof and 2-(1-oxoquinoxalinyl)disulfides in detergent compositions | COLGATE-PALMOLIVE COMPANY (US) | 1976-07-27 | — | — | US | disclosed |
| US-3971725-A | 2-Mercaptoquinoxaline-1-oxides, salts thereof and 2-(1-oxoquinoxalinyl)disulfides in detergent compositions | COLGATE-PALMOLIVE COMPANY (US) | 1976-07-27 | — | — | US | disclosed |
| US-3852443-A | 2-MERCAPTOQUINOXALINE-1-OXIDES, SALTS THEREOF AND-(1-OXOQUINOXALINYL) DISULFIDES FOR TREATING HAIR AND SKIN | COLGATE PALMOLIVE CO | 1974-12-03 | — | — | US | disclosed |
| US-3733323-A | 2-MERCAPTOQUINOXALINE-1-OXIDES,SALTS THEREOF AND 2-(1-OXOQUINOXALINYL)DISULFIDES | COLGATE PALMOLIVE CO | 1973-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124690-A1 | Pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4-[2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl]-1-oxaspiro[2,5]octan-6-one | SRD5A2, CYP17A1, SRD5A1 | CRHBP 2879/4885CRHR2 1773/4885KEAP1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.